The Tumor and Host Response (TIHR) program is a newly developed, interdisciplinary research group that focuses on the interaction between immunity and cancer. Investigators of the TIHR program perform basic and translational research aimed at understanding the role of Immune/Inflammatory responses in the pathogenesis of cancer and the application of these discoveries to the treatment of cancer. The program is comprised of 20 members from six different departments with a total annual direct research support of $6,542,810 of which $1,786,734 is from the NCI. Over this last grant period, there were 352 publications of the Tumor Immunology and Host Response Program, of which 13,6% are intra-programmatic and 34.7% are inter-programmatic. Investigators are involved in many intra- and inter-programatic interactions and collaborate with researchers in other University of Michigan Comprehensive Cancer Center programs including Cancer Cell Biology, Breast Oncology, Prostate Oncology, and Head and Neck Oncology. The program has recently joined the Translational Research Cancer Consortium (TRC3), consisting of Immunology programs of major Comprehensive Cancer Centers in the region, The TIHR program has three main research themes: (1) to elucidate the mechanisms that regulate the interaction between cancer cells and the Innate and adaptive immune systems;(2) development of novel approaches to enhance immune responses against cancer cells;and (3) the translation of novel discoveries from the laboratory to the clinic for cancer treatment.

Public Health Relevance

The program studies how the immune system interacts with tumor cells during cancer development. Our work will not only provide opportunity to induce better immune response for cancer prevention and therapy, but also elucidate critical host factors that facilitate cancer development for targeted cancer therapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Pinskey, Justine M; Franks, Nicole E; McMellen, Alexandra N et al. (2017) Neuropilin-1 promotes Hedgehog signaling through a novel cytoplasmic motif. J Biol Chem 292:15192-15204
Skolarus, Ted A; Metreger, Tabitha; Hwang, Soohyun et al. (2017) Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. Trials 18:181
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Mann, J E; Hoesli, R; Michmerhuizen, N L et al. (2017) Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. J Cancer 8:332-344
Maj, Tomasz; Wang, Wei; Crespo, Joel et al. (2017) Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol 18:1332-1341
Zhang, Jie; Feng, Shumei; Su, Wenmei et al. (2017) Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. Sci Rep 7:42819
Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2017) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 15:179-188
Birkeland, Andrew C; Foltin, Susan K; Michmerhuizen, Nicole L et al. (2017) Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. Oral Oncol 68:5-8
Walline, Heather M; Goudsmit, Christine M; McHugh, Jonathan B et al. (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840-852
Friese, Christopher R; Harrison, Jordan M; Janz, Nancy K et al. (2017) Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer 123:1925-1934

Showing the most recent 10 out of 1355 publications